Literature DB >> 23263161

Nebivolol treatment improves resistant arterial function and reduces ventricular hypertrophy and angiotensin II in spontaneously hypertension rats.

Yan Wang1, Ming Sheng Zhang, Yu Liu.   

Abstract

OBJECTIVE: The objective of this article is to assess the effects of nebivolol on resistant vascular reactivity, ventricular hypertrophy and the renin-angiotensin system in spontaneously hypertension rats (SHR).
METHODS: Rats were divided into: SHR treated with nebivolol (8 mg/kg, i.g.)/atenolol(80 mg/kg, i.g.); SHR control group; normotensive Wistar-Kyoto (WKY) control group. Vascular responses to KCl, noradrenaline (NA), endothelin-1 (ET-1), angiotensin II (Ang II), acetylcholine (ACh) and sodium nitroprusside (SNP) were tested on the femoral and renal artery. Left ventricle weight/body weight ratio (LVW/BW) was measured. Ang II and angiotensin-converting enzyme (ACE) activity in plasma and the left ventricle were determined. Plasma renin activity (PRA) was quantified.
RESULTS: Systolic blood pressure was decreased after nebivolol treatment in SHR. Compared with WKY, the contractions to KCl, NA, Ang II and ET-1 were increased in SHR while the relaxation to ACh was impaired. LVW/BW was higher in SHR. Levels of Ang II and ACE activity in plasma and the left ventricle were increased in SHR, but PRA was similar in these groups. Compared with atenolol, nebivolol markedly improved resistant vascular reactivity and decreased LVW/BW and Ang II. But nebivolol had no influence on ACE activity and PRA in SHR.
CONCLUSION: Nebivolol treatment improved resistant arterial reactivity and reduced left ventricular hypertrophy and Ang II in SHR.

Entities:  

Keywords:  Nebivolol; SHR; femoral artery; renal artery; renin-angiotensin system (RAS)

Mesh:

Substances:

Year:  2012        PMID: 23263161     DOI: 10.1177/1470320312470580

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  2 in total

1.  Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

2.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.